Vidac Pharma is one of the biotech shooting stars on the German stock market, with a share price increase of over 120% in the last 6 months. The Israeli company has a long history and is a pioneer in biopharmaceutical research. At the center of its oncology research is the Warburg effect, a phenomenon in which cancer cells metabolize glucose in large quantities. Vidac has developed a method that aims to inhibit hyperglycolysis and restore apoptosis in malignant cells. This targeted intervention could not only reduce the side effects of conventional chemotherapy but also make the tumor microenvironment adaptable to immune responses, increasing the effectiveness of other therapies.
News & Events